Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says

MT Newswires Live

Yesterday

Telix Pharmaceuticals (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.

Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.

Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.

It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.

The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/news/2667487616"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667487616\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667487616?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 13:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667487616","market":"sh","top_or_hot":-1,"title":"Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.</p><p>Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.</p><p>Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.</p><p>It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.</p><p>The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-15 13:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.</p><p>Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.</p><p>Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.</p><p>It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.</p><p>The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667487616","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667487616","pubTimestamp":1789450283,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Telix Pharmaceuticals  earnings per share  forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration  approval for its new drug application for Pixclara, according to a Monday note by Jefferies.Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.Pixclara is an amino acid positron emission tomography  drug for imaging glioma, a type of brain tumor.It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","PET.AU":"PHOSLOCK ENVIRONMENTAL TECHN","BK7047":"环境与设施服务","TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"杰富瑞表示，胶质瘤药物获批后，Telix 2027 财年每股收益预测将增长约 9%，2028 财年每股收益预测将增长约 21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PET.AU":1,"TLX.AU":1},"content_text":"Telix Pharmaceuticals (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}